The decision by the Data Monitoring Committee (DMC) to open cohort 2 follows the review of preliminarysafety and efficacy data and their recommendation is based on predefined safety and efficacy thresholds.
After 6 months....
For seven out of 17 (41.2 %) a partial response (PR) according to RECIST 1.1 was observed as the best overallresponse (BOR) as of the data cut-off (September 6, 2019) in this interim analysis.
An additional six patientshad a stabilization of disease (SD) as best overall response at this point leading to a disease control rate of76.5 % in this highly aggressive tumour entity. Twelve patients are currently continuing treatment.
Patientswere allowed to participate regardless of their PD-L1 status which is a well-known predictive marker forresponse to pembrolizumab in NSCLC.....
Ann: Immutep expands Part A of TACTI-002 due to positive data, page-8
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2506 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 8079 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |